Translational Medicine in CNS Drug Development (eBook, ePUB)

Redaktion: Nomikos, George G.; Feltner, Douglas E.

• Format: ePub

Produktbeschreibung

Translational Medicine in CNS Drug Development, Volume 29, is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques. With extensive coverage on all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, this book presents an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for the successful development of drugs to treat central nervous system disorders.

Despite increases in the number of individuals suffering from CNS-related disorders, the development and approval of drugs for their treatment have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and CNS to pharmacodynamic measures in both animals and humans.

• Includes comprehensive coverage of biomarker tools and the role of personalized medicine in CNS drug development
• Discusses strategies for drug development for a full range of CNS indications, with particular attention to neuropsychiatric and neurocognitive disorders
• Includes chapters written by international experts from industry and academia

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science & Techn.
• Seitenzahl: 458
• Erscheinungstermin: 18. Juni 2019
• Englisch
• ISBN-13: 9780128031643
• Artikelnr.: 52014629

Inhaltsangabe

1. Translating animal models of obesity and diabetes to the clinic
2. Biomarker-guided drug development for better defined early patient
studies and clinical trial efficiency
3. Modeling and simulation in the translational pharmacology of cns drugs
4. Functional measurements of central nervous system drug effects in early
human drug development
5. Experimental medicine approaches in cns drug development
6. New approaches in translational medicine for phase i clinical trials of
cns drugs
7. Translational approaches for antidepressant drug development
8. Biomarker opportunities to enrich clinical trial populations for drug
development in schizophrenia and depression
9. Applications of neuroimaging biomarkers in cns drug development
10. Pet occupancy and competition in translational medicine and cns drug
development
11. Stable isotope labeling kinetics in cns translational medicine:
introduction to silk technology
12. Applications of neurophysiological biomarkers in cns drug development:
focus on psychoses
13. Heart rate variability as a translational biomarker for emotional and
cognitive deficits
14. Drug discovery in psychiatry: time for human genome-guided solutions
15. Use of cognition to guide decisions about the safety and efficacy of
drugs in early-phase clinical trials
16. Digital biomarkers in clinical drug development
17. Lessons learned from public private partnerships and consortia: the
adni paradigm
18. Regulatory perspectives on the use of biomarkers and personalized
medicine in cns drug development: the fda viewpoint
19. Regulatory considerations for the use of biomarkers and personalized
medicine in cns drug development: a european perspective
20. Regulatory science objectives and biomarker qualification through
public-private partnerships are critical to delivering innovative
treatments for cns diseases
21. The assessment of cognition in translational medicine: a contrast
between the approaches used in alzheimer's disease and major depressive
disorder
22. Translational medicine strategies in drug development for
neurodevelopmental disorders
23. Translational medicine strategies in drug development for mood
disorders
24. Translational medicine strategies in alzheimer's disease drug
development
25. Experimental medicine models in generalized anxiety disorder and social
anxiety disorder
26. Translational medicine strategies in ptsd drug development
27. Unmet medical needs in the treatment of depression and the clinical
development of a differentiated antidepressant: a translational line of
evidence
28. Translating neurobiology into practice in tobacco, alcohol, drug, and
behavioral addictions
29. Translational medicine strategies for drug development for impulsive
aggression
30. Hypothesizing major depression as a subset of reward deficiency
syndrome (rds) linked to polymorphic reward genes: considerations for
translational medicine approaches for future drug development
31. Traveling through the storm: leveraging virtual patient monitoring and
artificial intelligence to observe, predict, and affect patient behavior in
cns drug development